XML 50 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Combinations and Contingent Consideration (Tables)
6 Months Ended
Jun. 30, 2018
Talon Therapeutics, Inc. [Member]  
Business Acquisition [Line Items]  
Change in Fair Value of Contingent Consideration Related to Acquisitions
 
Fair Value
of Talon
CVR
December 31, 2017
$
6,210

Fair value adjustment for the six months ended June 30, 2018
483

June 30, 2018
$
6,693

Acquisition-Date Fair Value of Consideration Transferred
The acquisition-date fair value of the consideration transferred consisted of the following:
 
 
Cash consideration
$
3,000

Ligand contingent consideration
4,700

Total purchase consideration
$
7,700

Melphalan license [Member]  
Business Acquisition [Line Items]  
Summary of Allocation of Total Purchase Price to Net Assets Acquired
The allocation of the total purchase price to the net assets acquired is as follows:
EVOMELA IPR&D rights
$
7,700